{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01666808\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"EMPIRE-1","nct_id":"NCT01666808","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=empire-1-nct01666808. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"A trial group in which anti-3-\\[18F\\]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.","label":"FACBC PET scan","type":"EXPERIMENTAL"},{"description":"A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.","label":"Conventional-Only Imaging","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2022-04-18","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":165,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"FACBC","otherNames":["anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid"],"type":"DRUG"},{"name":"Radiation therapy","otherNames":["Intensity-modulated radiotherapy (IMRT)"],"type":"RADIATION"}],"last_update":"2023-08-02","lead_sponsor":"Emory University","official_title":"Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2022-04-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Failure-free Survival","timeFrame":"3-Year post-intervention"}],"references":[{"citation":"Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ, Shelton JW, Patel PR, Xu KM, Goodman M, Master VA, Joshi SS, Kucuk O, Carthon BC, Bilen MA, Abiodun-Ojo OA, Akintayo AA, Dhere VR, Schuster DM. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021 May 22;397(10288):1895-1904. doi: 10.1016/S0140-6736(21)00581-X. Epub 2021 May 7.","pmid":"33971152","type":"RESULT"},{"citation":"Dhere VR, Schuster DM, Goyal S, Schreibmann E, Hershatter BW, Rossi PJ, Shelton JW, Patel PR, Jani AB. Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomography-Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic Effects. Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):1003-1014. doi: 10.1016/j.ijrobp.2022.04.005. Epub 2022 Apr 11.","pmid":"35417762","type":"RESULT"}],"start_date":{"date":"2012-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"FACBC Outcomes for Post Prostatectomy","url":"https://clinicaltrials.gov/study/NCT01666808"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/empire-1-nct01666808"}